bioTheranostics Announces Contract with Three Rivers Provider Network
bioTheranostics Signs Agreement with National PPO Network Prime Health Services
bioTheranosticsâ€™ Breast Cancer IndexSM Molecular Test Identifies Risk for Early and Late Breast Cancer Recurrence, Lancet Oncology Study Finds
Medical Laboratory Observer:
Under Richard Dingâ€™s direction, bioTheranostics focuses on biomarkers to aid in cancer treatment
Journal of Clinical Oncology:
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute
Gene Profilingâ€“guided Therapy May Improve Survival in Patients with Carcinoma of Unknown Primary
bioTheranostics develops and provides innovative oncology tests to support targeted disease management.
bioT3 is a suite of genomic-based tests that provide diagnostic and therapeutic information for metastatic cancer patients at any stage across the continuum of care.
Breast Cancer IndexSM (BCI) provides full risk assessment, with the unique ability to predict both early and late recurrence, as well as benefit from extended endocrine therapy.
Learn More >
Learn more about bioT3
Access Clinical Publications
Register for Clinical Updates
Request a Specimen Shipping Kit
Contact Medical Affairs
Learn More About Metastatic Cancers